Hauschild Axel, Gogas Helen, Tarhini Ahmad, Middleton Mark R, Testori Alessandro, Dréno Brigitte, Kirkwood John M
Department of Dermatology, University of Kiel, Kiel, Germany.
Cancer. 2008 Mar 1;112(5):982-94. doi: 10.1002/cncr.23251.
Interferon-alpha-2b (IFNalpha2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this agent. A review of the literature demonstrated little recent attention to supportive care in the management of IFN toxicities. An international group of experts with extensive personal experience in the use of IFNs worked together to develop practical guidelines for the use of IFNs. Practical recommendations were developed for patient education on the use of IFN; initial patient assessment and monitoring, including contraindications to the use of IFN, monitoring and managing adverse events, and IFN dose modification and discontinuation; IFN injection procedures; treatment of elderly patients; and use during pregnancy and nursing. Successful adjuvant therapy of melanoma with high-dose IFN requires close compliance with the treatment regimen. Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment.
干扰素-α-2b（IFNα2b）是全球监管机构批准的、唯一用于复发风险高的黑色素瘤患者的有效辅助治疗药物。然而，干扰素的毒性增加了治疗依从性差的风险，并削弱了从该药物中获益的可能性。文献综述表明，近期很少有人关注干扰素毒性管理中的支持性护理。一组在干扰素使用方面具有丰富个人经验的国际专家共同制定了干扰素使用的实用指南。针对干扰素使用的患者教育制定了实用建议；初始患者评估和监测，包括干扰素使用的禁忌症、不良事件的监测和管理以及干扰素剂量调整和停药；干扰素注射程序；老年患者的治疗；以及妊娠和哺乳期的使用。大剂量干扰素成功辅助治疗黑色素瘤需要严格遵守治疗方案。不良事件识别和管理的建议旨在使更多患者能够完成完整的计划治疗疗程。
